JBM HEALTHCARE (02161) announces its interim results. The profit attributable to equity holders is approximately HK$95.9 million, representing an increase of approximately 53.4% year-on-year. A dividend of HK$0.055 per share will be distributed.

JBM HEALTHCARE (02161) announced its interim performance for the six months ending September 30, 2024, with revenue of approximately HK$399 million, an increase of about 22.1% year-on-year. Operating profit was approximately HK$121.6 million, an increase of about 41.7% year-on-year. Profit attributable to equity holders of the company was approximately HK$95.9 million, an increase of about 53.4% year-on-year. Earnings per share were 11.63 HK cents, with an interim dividend of 5.5 HK cents per share. The announcement stated that the strong profit growth was mainly attributed to the outstanding sales performance of the core brands, particularly Hejigong in the branded medicine division and Baojiwan in the branded Chinese medicine division. The group's concentrated Chinese medicine granule business also maintained stable growth momentum. These achievements reflect the group's successful implementation of integrated online and offline sales and marketing strategies, effectively capturing the growth opportunities in the urban markets of Hong Kong, Macau, and the Greater Bay Area.